Clinical trials: Mast Cell Disorder
Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
- Trial name
- NCT05652907
- Testing
- FSD201
- Where
- 3 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Quantum Biopharma
Indolent Systemic Mastocytosis
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
Background: Mast cells help the body fight disease and heal wounds. People with indolent systemic mastocytosis (ISM) make too many mast cells. This causes pain, tiredness, digestive problems, and other symptoms.
- Trial name
- NCT03770273
- Testing
- sarilumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)
- Conditions
- Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
- Trial name
- NCT00233454
- Testing
- Midostaurin
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Jason Robert Gotlib
Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
This clinical trial studies bioelectrical impedance measurement for predicting treatment outcome in patients with newly diagnosed acute leukemia.
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT01869777
- Testing
- bioelectric impedance analysis
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Wake Forest University Health Sciences
Allergic Rhinitis
The Effect of Omalizumab on Responses to Cat Allergen Challenge
This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, skin and blood that cause allergies.
- Trial name
- NCT00604786
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Cutaneous Mastocytoses
Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis
The purpose of this study is to determine the effectiveness and tolerability of a novel topical preparation for the treatment of cutaneous lesions of mastocytosis.
- Trial name
- NCT04846348
- Testing
- Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph Butterfield
Anemia, Leukemia
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00416624
- Testing
- darbepoetin alfa, epoetin alfa, fatigue assessment and management
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- Mayo Clinic
Leukemia, Mast-Cell, Mantle-cell Lymphoma
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)
- Trial name
- NCT00186628
- Testing
- Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Stanford University
Systemic Mastocytosis
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
The goal of this clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied.
- Trial name
- NCT00449748
- Testing
- RAD001 (Everolimus)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Fibromyalgia
Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study
The purpose of this 10-week study is to determine the effects of a medication called Ketotifen on pain sensitivity; and fibromyalgia-related pain.
- Trial name
- KetoforFMS (NCT01553318)
- Testing
- Ketotifen
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Indiana University